

it has already developed, to treat clinical cancer.

Sub  
92  
2. A vaccine product, which is a Recognin or a derivative thereof which contains the immunological specificity of malignin, Recognin L or Recognin M, which upon administration to humans or animals, will cause to be inhibited or destroyed cancer cells, regardless of cell type, and prevent the development of clinical cancer, or if it has already developed, treat clinical cancer by destroying them or by inhibiting their growth.

3. A vaccine product which is DNA or RNA or a derivative thereof, which upon appropriate administration to humans or animals will lead to the production of a Recognin or a derivative thereof which contains the immunological specificity of malignin, Recognin L or Recognin M, which in turn will will cause to be inhibited or destroyed cancer cells, regardless of cell type, and prevent the development of clinical cancer, or if it has already developed, treat clinical cancer.

4. A product which has the characteristics of an antibody to malignin and the Recognins L and M, alone or bound to other agents cytotoxic to cancer cells.

5. A product which has the characteristics of a cell or mechanism with immunological specificity for malignin and the Recognins L and M which will remove, destroy or inhibit the growth of cancer cells.

6. A product according to claim 5. where the cell is T cell, a B cell, or a phagocytic cell.

7. A product according to claim 5. where the cell is a device or mechanism which when in contact with cancer cells would bind, adsorb or engulf them so as to remove them from the body,

where the device or mechanism is a filter or column or resin or surface through which or on which the cancer cells are made to pass or come in contact.

8. A process for quantitatively assessing the immune status of an individual human or animal with regard to the level of their anti-cancer defences, and with regard to whether malignant cells are present or not, by determining the quantity of anti-Recognin antibody and the quantity of immune cells specific for malignin and Recognins L and M in their serum or other body fluids or tissues.